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ABSTRACT
Pancreatic cancer remains one of the deadliest cancers. The five-year survival 
rates have been reported as 3%. Radical surgical tumor resection is critical for 
improved outcome and the low survival rate for pancreatic cancer is due to lack of 
other effective treatments and here optical guided surgery could be a solution for 
better surgical outcome. In the present study, we targeted the urokinase plasminogen 
activator receptor (uPAR) with a peptide conjugated with the fluophore ICG (ICG-
Glu-Glu-AE105) for optical imaging. In the first part of the study we aimed to validate 
ICG-Glu-Glu-AE105 for resection of the primary tumor and metastases in an orthotopic 
human xenograft pancreatic cancer model. In the second part of the study we aimed to 
investigate if fluorescent-guided imaging could locate additional metastases following 
conventional removal of metastasis under normal white light surgery.
Our study showed that ICG-Glu-Glu-AE105 was an excellent probe for 
intraoperative optical imaging with a mean tumor-to-background ratio (TBR) for 
the primary tumor of 3.5 and a TBR for the metastases of 3.4. Further, a benefit 
using intraoperative fluorescent guidance yielded identification of an additional 14% 
metastases compared to using normal white light surgery. In 4 of 8 mice there were 
identified additional metastases with uPAR optical imaging compared to white light.
In conclusion, the uPAR-targeted optical probe ICG-Glu-Glu-AE105 enables 
intraoperative optical cancer imaging, including robotic surgery, and may be a benefit 
during intended radical resection of disseminated pancreas cancer by finding more 
metastasis than with traditional white light surgery.
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INTRODUCTION
Pancreatic cancer remains one of the most lethal 
cancer types and is the fourth leading cause of cancer-
related deaths the United States [1, 2]. Patients are often 
diagnosed in an advanced stage of disease where radical 
tumor resection is no more an option. Thus 80% of the 
diagnosed patients are treated with a palliative intention 
only. Despite intense research in pancreatic cancer over the 
past decade, the 5-year survival rate remains at only 3%. 
In 20% of the patients that are suitable for surgery, the vast 
majority experience relapse, and surgery only increases the 
median survival with 9.1 months from 3.5 to 12.6 months 
[3]. Hence, improved and more precise surgical procedures 
are urgently needed. A new technique that has emerged in 
the surgical field in recent years is real-time intraoperative 
optical imaging. This technology enables the surgeon to 
locate and delineate tumor lesions guided by a targeted 
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fluorescent signal using a near-infrared (NIR) camera 
[4, 5]. Until now passive retention in tumor lesions due 
to the enhanced permeability and retention (EPR) effect 
of larger molecules as indocyanine green (ICG) has been 
used to visualize tumor lesions [6]. This works well in 
theory, but the EPR effect has shown great heterogeneity 
in different tumors and therefore it cannot be applied as 
a global cancer marker [7]. Thus, cancer specific probes 
are needed for better guidance across different types of 
cancer. Clinical trials investigating new optical compounds 
in cancer surgery are currently ongoing. Accordingly, the 
OTL38 probe targeting the folate receptor has recently been 
through a Phase I study [8] and has entered Phase II studies 
[4]. Likewise, an EGFR targeting antibody cetuximab 
labelled with the fluophore IRDye800 has also shown 
promising results in phase I and II studies [9]. However, 
the heterogeneous expression of biomarkers in different 
cancer types highlights the need for new targets and probes 
for imaging of a broader group of cancer patients.
Urokinase-type plasminogen activator receptor 
(uPAR) is a membrane-bound protein highly expressed 
in most cancer types including pancreatic cancer [10], 
oral cancer [11, 12], glioblastomas [13], breast cancer 
[14], and colorectal cancer [15]. In pancreatic cancer, 
uPAR is often expressed at the invasive front of the tumor 
and in the immediately surrounding activated stromal 
component [16]. Accordingly, uPAR is an ideal target for 
intraoperative imaging for delineation of cancer tissue. 
As uPAR is a well-known marker for tumor invasion and 
aggressive disease, our group previously developed uPAR 
PET tracers using the same peptide (AE105) [17, 18] that 
are currently undergoing Phase II testing in several types 
of cancer. Taking offset in an uPAR-targeting platform, 
we therefore further developed our targeting peptide into 
an optical imaging probe using ICG as fluorophore [19]. 
This strategy offers a unique opportunity to combine 
pre-operative PET imaging, for selection of patients 
eligible for intraoperative use of uPAR optical imaging. 
We have previously validated the rational of combined 
uPAR-directed PET and optical imaging in a preclinical 
study [20]. Preoperative uPAR PET imaging provides a 
tool to better evaluate the extent of the tumor resection 
needed and the expression level of the receptor, which is 
vital when planning surgery. Using uPAR guided optical 
surgery improves the possibility of obtaining surgical 
radicality in regards to margins and finding additional 
metastasis and thereby improve long term survival.
The aim of the present study was therefore to 
investigate if the use of the uPAR-targeted optical probe 
ICG-Glu-Glu-AE105 in an orthotopic xenograft model 
of human pancreatic cancer could improve the surgical 
outcome by detecting additional cancer lesions not found 
during white light surgery.
RESULTS
In the first part of the study, where the aim was 
to show the feasibility of the probe in an orthotopic 
pancreatic human xenograft cancer model, both the 
primary tumor and metastatic lesions were detected by 
the use of the fluorescent signal in vivo. Tumor cells were 
luciferase (luc) transfected and could thus be detected 
with not clinically translatable bioluminiscence (BLI) as 
a reference. Imaging of the primary tumor showed a clear 
delineation of the tumor lesion located in the pancreas with 
a very low background signal (Figure 1A). During imaging 
of the metastatic lesions, all foci visible by the naked eye 
were also detected with the fluorescent signal. In addition, 
Figure 1: Fluorescent images of pancreatic tumors. (A) Representative fluorescent image of a primary tumor developed after 
inoculation of the cell line BxPC3. luc2 in the tail of the pancreas. The image was taken 15 h post iv. injection of ICG-Glu-Glu-AE105 with 
the clinically approved fluorescent camera Fluobeam800® (B). Several days after removal of the primary tumor small tumor metastases 
developed in the peritoneal cavity and were clearly visible by fluorescent imaging after iv. injection of ICG-Glu-Glu-AE105. In both 
images the fluorescent image is processed in Image J and merged with a white light image.
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several foci, were only detected by the fluorescent signal 
(Figure 1B). Lesions down to less than one millimeter, that 
were not possible to detect with white light, could only be 
detected with fluorescent imaging. Tumor-to-background 
(TBR) values for the primary tumors and the metastatic 
lesions were 3.5 (95% confidence interval (Cl): 3.3; 3.7) 
and 3.4 (Cl: 3.1; 4.0), respectively (Table 1).
Supplementary Video 1 demonstrates the feasibility 
of the probe to localize millimeter foci. A metastasis in the 
abdominal region was easily identified with the Fluobeam 
camera and then resected by the surgeon. In this situation a 
small residual deposit was left behind during the resection 
but was clearly picked up by the camera and enabled 
the surgeon to perform a complete radical resection by 
removing the foci detected.
The second part of the study aimed to evaluate if 
optical imaging could identify additional metastases 
after all metastases visible with white light had been 
removed (Table 2). On a lesion-basis, a total of 43 positive 
metastases identified with bioluminescence (mean = 5.4 
(range: 3–7) were present in the 8 mice. Of these 43 
metastases, 29 metastases were found without fluorescent 
guidance (white light), and an additional 6 metastases 
were identified only with the Fluobeam®800 camera 
(Figure 2A, 2B). Finally, an additional 8 metastases 
were found only with non-translatable bioluminescence 
imaging. On an individual-basis, in 4 of the 8 mice (50%) 
there were identified additional metastases with uPAR 
optical imaging compared to white light. Hence, in 50% 
of the mice the surgeon operated in white light there would 
have been left behind metastases that could be found with 
uPAR optical imaging.
To explore the feasibility of NIR fluourescense-
guided surgery of pancreatic cancer in a clinically relevant 
setup, we performed surgery in one mouse using the da 
Vinci® HD Si surgical robotic system. The mouse was 
similar to the other mice in the study, with an orthotopic 
pancreas tumor and the procedure was performed as open 
surgery. After the abdomen was opened and the region 
of the pancreas was located, the firefly NIR fluorescence 
function in the robot was activated (Figure 3), and a clear 
fluorescent signal confined to the tumor was observed. 
Further, switching between NIR imaging and white light 
imaging in the robot to evaluate anatomy, permitted 
instant integration of the two modalities. The fast change 
between white light and fluorescent light enables an easy 
and intuitive guidance by the fluorescent signal along 
with high quality colour imaging of the anatomy to allow 
optimal surgical navigation (see Supplementary Video 2).
DISCUSSION
In the present study the novel optical uPAR targeted 
probe ICG-Glu-Glu-AE105 was able to demonstrate 
clear localization of tumor deposits in an orthotopic 
human xenograft pancreas tumor model. Furthermore, 
with the optical probe a substantial number of additional 
metastases, not found during white light surgery, were 
identified. We therefore suggest, that uPAR optical 
guided surgery has the potential to improve outcomes in 
pancreatic cancer surgery.
For many years surgical oncology has relied on the 
surgeon’s subjective assessment on delineating tumor 
tissue from the surrounding healthy tissue based on 
the use of palpation and visual inspection under white 
surgical light to decide the extent of surgery. Radical 
resection is the primary treatment in the majority of solid 
tumors and presence of positive margins is of upmost 
Table 1: Tumor-to-background (TBR) values for primary tumor and metastases
Mean TBR 95% confidence interval
Primary tumor 3.5 (n = 5) 3.3; 3.7
Metastases 3.4 (n = 9) 3.1; 4.0
Some metastases were down to 1 mm3 and still clearly visible. Tumor to background values.
Table 2: Number of metastasis found during surgery
Number of  
metastases/number of 
mice
Percentage of total 
number of metastasis 
found
95% confidence interval
Metastasis
Found with white light 29 67% 52; 81%
Additionally found with FGS 6 14% 5; 28%
Mice
Mice with additional metastasis only 
found with FGS 4 50% 16; 84%
All mice (n = 8) developed metastasis, and in 50% of the mice additional metastases were found after turning the 
fluorescent camera on. FGS: Fluorescense guided surgery using ICG-Glu-Glu-AE105. Number of metastasis found during 
surgery.
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importance to avoid, because even small deposit of tumor 
cells left behind increase the risk of recurrence. Optical 
guidance during surgery has therefore been introduced in 
the surgical field and show promising results both with 
untargeted and targeted optical probes. The predominant 
compound that has been used for passive accumulation in 
sentinel lymph nodes and primary tumor lesions is ICG [6]. 
It is well known that ICG retention in the sentinel lymph 
Figure 3: Images of a primary orthotopic pancreas human xenograft tumor as seen with the robotic Da Vinci® system. 
This system allows the surgeon to switch between normal colour image and a fluorescent image. The image is taken 15 h post injection of 
ICG-Glu-Glu-AE015 after an incision in in the abdomen. (A) Image represent a normal white light operating view while image (B) is the 
fluorescent view with NIR vision turned on.
Figure 2: Presentation of one of the mice enrolled in the study part II where comparison of white light surgery and 
fluorescent guided surgery was the aim. (A) Fluorescent image of orthotopically placed primary pancreas tumor 15 h post injection 
of ICG-Glu-Glu-AE105. (B) Fluorescent image of a metastases left behind after surgery with white light only. This metastases was detected 
with the fluorescent camera Fluobeam800® only and was not visible during white light operation. (C) Bioluminescence was used as the 
gold standard for verification of the presence of tumor cells. All suspected foci (white light and fluorescent) were investigated for presence 
of tumor cells from a bioluminescence image. (D) Table overview of suspected tumor foci found throughout the surgery of a representative 
mouse. No. 1–4 were found under normal surgery condition, no. 5–6 were found after turning the fluorescent camera on. No. 7 was found 
only by imaging the animal after ended surgery with bioluminescence.
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nodes is due to high affinity for albumin and therefore 
drainage by the lymphatic system, while the EPR effect 
is the main mechanism for the fluorophore to accumulate 
in the primary lesion. Therefore, free ICG is only suitable 
to detect tumors with high vascularity and is not tumor 
specific. Furthermore, the EPR effect is known to be 
highly variable [7]. For specific targeting of the tumor 
lesion, a receptor or surface protein highly expressed on 
the cancer cells is necessary for development of an agent 
that can accumulate and increase the fluorescent signal 
from tumor and metastases.
Biomarkers for cancer have been heavily studied 
during the last decade. Several biomarkers have shown high 
expression in specific cancers, which makes them potential 
targets for fluorescent probes for use in fluorescent guided 
surgery. Several fluorescent probes have been developed, 
to target these biomarkers, but only a few have entered 
clinical trials including probes targeting EGFR [9], folate 
[8], CEA [21] and bombesin receptors (NCT02910804). 
Even though these probes show promising results, tumor 
lesions are prone to heterogeneity and it may be of key 
importance to identify targets that are expressed by 
the majority of the tumors present in a patient group as 
translation into clinical use has proved difficult, time 
consuming and expensive, mainly due to dose challenges 
and regulatory requirements [22]. Even though ICG may 
not be an optimal fluorophore in terms of kinetic and 
fluorescent properties, it has the advantages of having been 
used extensively clinically as an intravenous agent since 
the 1950’s. Given the favorable safety profile of ICG and 
the fact that the peptide moiety AE105 has been used in 
more that 300 patients included in a number of clinical 
uPAR-PET Phase I/II trials without any side-effects [17, 
18] (NCT02964988, NCT02945826, NCT02681640, 
NCT03278275, NCT02960724, NCT02965001 and 
NCT03307460), ICG-Glu-Glu-AE105 is an attractive 
agent for clinical translation compared with other imaging 
agents, where both targeting moiety and fluorophore may 
not have been tested in humans before. The PET probe 
already developed and tested in several cancer types at 
our department would also be useful in stratifying patients 
suited for targeted intraoperative optical imaging, i. e. if the 
uPAR PET scan is positive in the tumor/metastases, then 
uPAR optical guidance will be relevant. As a biomarker 
uPAR exhibits abilities important for use in fluorescence 
guided surgery. uPAR is expressed in many cancer types 
including breast, prostate, head & neck, glioblastoma, 
colorectal and pancreas cancer. Expression of uPAR is 
often highest at the tumor margin and in the surrounding 
activated tumor-associated stroma. The stroma plays a 
major role in pancreatic tumor, with up to 90% of the tumor 
volume consisting of stroma cells potentially uPAR positive 
[23]. A study which investigated biomarker expression in 
pancreatic adenocarcinomas, has shown that in 66% of 
patients, neoplastic cells had elevated uPAR expression 
while 82% had high expression in stroma associated cells 
[24]. This makes uPAR an ideal marker particular when the 
margins are uPAR positive. A fluorescent probe targeting 
both tumor and stroma is therefore an advantage to improve 
the number of negative margins and radical resections with 
fluorescence guided surgery.
One of the uPAR-targeted optical probes that has 
been investigated is the antibody based uPAR-targeted 
multimodal tracer ZW800-111In-ATN-658, which was tested 
in a head & neck cancer animal model [25]. However, the 
use of antibodies as targeting agent compared to peptides 
has both advantages and disadvantages. Antibodies are 
easier to conjugate to a fluorophore or chelator without 
influencing the affinity for the target. However, the major 
disadvantage with antibodies for optical imaging is the 
pharmacokinetics, where the long clearance time makes 
them potentially unsuitable as imaging agents compared 
to smaller proteins and peptides with fast kinetics and 
clearance from the background [26]. Antibodies have an 
optimal imaging time window from 24–72 h, which is 
impractical for surgery from a logistic point of view. This 
can partly be overcome by using affibodies or nanobodies 
as previously demonstrated [27, 28]. Affibodies still keep 
the specificity for the target and are easy to conjugate 
while the clearance time is substantially lowered compared 
to a full antibody. However, from a kinetic point of view 
peptide based ligands still may be the ideal choice. The 
first optical uPAR tracer was based on the aminoterminal 
fragment ATF of uPA [29]. This tracer showed promising 
results but was conjugated to the NIR fluorophore Cy5.5 
that is not suitable for use in humans. Also, due to a long 
circulating time the imaging window was around 24 h. 
With these considerations in mind the optimal tracer in our 
view consists of a small peptide conjugated to a bright and 
non-toxic fluorophore.
Our results showed that the peptide based uPAR 
ligand ICG-Glu-Glu-AE105 tracer circulated in the blood 
and accumulated in the tumorous tissue to obtain a mean 
TBR of 3.5 in the primary lesions. This is well above 
the minimum of a TBR of 2 which is generally accepted 
necessary as a rule-of-thumb in order to effectively 
delineate lesions. Also, the metastases demonstrated a 
high TBR of 3.4. Metastases identified during fluorescent 
guided imaging were as small as 1 mm and still clearly 
visible. This demonstrate that our optical tracer together 
with a NIR camera is able to detect metastasis in the 
millimeter range and satellite branches of the tumor 
lesion during surgery even though not visible with the 
naked eye under white operation light. These findings are 
in concordance with our previous study that identified 
submillimeter tumor deposits in the neck lymph nodes 
in an orthotopic tongue cancer model by use of optical 
guidance [20]. Imaging time after injection for our optical 
tracer has been evaluated in a previous study [19], and 
was found to be high between 6 hours and up to 24 hours 
and is therefore very compatible with the clinical routine. 
Both clinically approved camera systems, Fluobeam800® 
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and the da Vinci Surgical System® are sensitive enough to 
visualize weak signals from the tumors, while the da Vinci 
Surgical System® has the advantage of quick switching 
between white light anatomy and the fluorescent signal.
The second part of our study showed that the use 
of fluorescence guided surgery improved surgery by 
identifying additional metastases in 50% of the mice. Based 
on total number of metastases identified, an additional 14% 
(95% CI: 5;28) metastases were found using the uPAR 
optical guidance.
In conclusion, our study showed that ICG-Glu-Glu-
AE105, targeting uPAR, is a promising imaging agent for 
fluorescence guided surgery. With uPAR guided surgery 
additional metastases were found in 50% of the mice 
suggesting that uPAR optical guidance may lead to better 
surgical outcome. Our findings support clinical translation 
of ICG-Glu-Glu-AE105.
MATERIALS AND METHODS
Materials
The peptide AE105 [30] was conjugated via 
the α-aminogroup to ICG and purchased from ABX 
(Radeberg, Germany) [19]. For in vivo injection ICG-
Glu-Glu-AE105 was dissolved in (2-hydroxypropyl)-
β-cyclodextrin with 2% DSMO. The human pancreas 
adenocarcinoma cell line BxPC3-luc2 was purchased 
from PerkinElmer and grown after the recommendations 
in RPMI-Glutamax with 10% FBS and 1% PenStrep.
Animal model
All animal experiments were performed under a 
protocol approved by the Animal Research Committee of 
the Danish Ministry of Justice (2016-15-0201-00920). The 
mice were anesthetized with 4% sevoflurane before an 
incision in the abdomen was made over the spleen and the 
pancreas was located. 5 × 105 BxPC3-luc2 in 25 ml PBS 
was injected orthotopic in the tail of the pancreas. The 
incision was closed with 5.0 suture. The primary tumor 
was followed by luminescence and when a suitable size 
was reached a similar incision was made and the primary 
tumor was removed and the incision was closed again as 
described above. During the study all mice were housed 
in groups with 12 h light/dark cycle with food and water 
available ad libitum.
Camera
The FluobeamR800 (Fluoptics, Grenoble, France) 
used for navigation during resection of the primary tumor 
and the metastases is a handheld camera with an excitation 
wavelength at 800 nm where adjustments as sensitivity 
and zoom are possible. We used the clinically approved 
surgical robot system da Vinci® HD Si, (Intuitive Surgical, 
California, USA) using non-human instruments, in one 
case for navigation in resection of a primary human 
xenograft tumor in the pancreas of a mouse. IVIS Lumina 
XR, a black-box optical camera was used for luminescence 
imaging for growth monitoring of the tumor and positive 
control for tumor presence in the resected metastases.
Part I – feasibility of optical imaging in an 
orthotopic pancreas model
After inoculation of BxPC3-luc2 cells in the pancreas 
as described above the mice were luminescence imaged to 
follow the growth of the primary tumor. When the primary 
tumor reached a suitable size of approximately 50–100 
mm3, 10 nmol of ICG-Glu-Glu-AE105 was injected i.v. 
into the mouse 15 h pre-operatively. The primary tumor was 
then removed and a fluorescent image of the tumor was 
performed throughout the surgery. Because it is known that 
removal of the primary tumor does not prevent metastases 
in the peritoneum from developing, the incision was closed 
and the mice underwent luminescence imaging to track 
the development of potential metastases. When potential 
metastatic burden was assessed in the abdomen, an incision 
was again made in the abdomen and the fluorescent camera 
was turned on to locate and image the metastases developed. 
TBR was later measured using ImageJ software, where a 
ROI was drawn over the whole tumor and a background 
ROI was drawn over adjacent tissue.
Figure 4: Study timeline over part II of the study, where white light surgery is compared with fluorescent guided 
surgery in 5 mice with ICG-Glu-Glu-AE105 was used as optical probe 15 h post iv. injection. The tumor growth was 
followed with bioluminescence before surgery to ensure tumor size and spread and was done after surgery to ensure that residual tumor 
foci were located after surgery.
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Part II – white light guidance compared to 
fluorescent guidance
The same work flow as in study I, except that the 
surgeon was asked to remove all the metastases he could 
identify with regular white light turned on during surgery. 
When the surgeon was convinced all metastases were 
removed the NIR camera was used to identify potentially 
additional metastases. The mouse was then imaged with 
bioluminescence to locate further metastases that was 
missed by both white light and NIR light (Figure 4). All 
metastases were imaged ex-vivo to validate the presence of 
tumor cells in the tissue assumed to be a metastasis. The 
mice were euthanized after the operation.
Statistical methods
Data are described as mean and 95% confidence 
interval.
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